Abstract:Highlights • Optimized OFDF formulation applicable to a broad range of drugs. • Experimental design using a 3 3 full factorial Box-Behnken design. • Formulation development for co-administration of two phytochemicals. • Utilization of co-amorphous dual-drug systems to enchance film morphology and drug dissolution. • Better in vitro performance with higher drug payload and less excipients. • A streamlined approach for improving the dissolution of insoluble drugs. Oral fast dissolving films (OFDFs) are popular dosage forms for enhanced oral absorption of active ingredients without experiencing gastrointestinal interference or first-pass metabolism. The primary challenge in OFDF design is balancing drug loading capacity with film properties, particularly for poorly soluble drugs. In the present work, an OFDF formulation containing co-amorphous mixture was successfully designed for co-administration of two natural products at a drug content of 14%. Breviscapine and matrine are commonly used for cardiovascular and cerebrovascular related diseases, but their clinical application was limited by low bioavailability, short biological half-life, and instability problems. Their co-administration as a compound remedy requires a novel product too enhance drug dissolution and patient compliance. A 3 3 Box-Behnken design was used to generate OFDF preparations by solvent casting method. The optimized blank film formulation, comprising 57.40% HPMC E50, 14.01% PEG 400 and 5.35% L-HPC, demonstrated a rapid disintegration in 18 seconds. XRD and FTIR analysis on drug-loaded films revealed good compatibility of drugs and polymers, and amorphous state of films with co-precipitates. The films were evaluated for morphology, folding endurance, disintegration time and in vitro BRE dissolution. Drugs incorporation extended the disintegration time of blank films, yet remained under 30 seconds. The co-amorphous mixture of BRE and MAT in films exhibited a faster BRE dissolution rate compared to the physical mixture. In conclusion, a compound OFDF formulation featuring a co-amorphous mixture of BRE and MAT offers an efficient strategy for hydrophobic drug delivery at high dose. Graphical abstract Download : Download high-res image (290KB) Download : Download full-size image

Evaluation of the Impacts of Formulation Parameters on the Pharmacokinetics and Bioequivalence of Risperidone Orodispersible Film: a Physiologically Based Pharmacokinetic Modeling Approach

Physiologically Based Pharmacokinetic Modeling to Understand the Absorption of Risperidone Orodispersible Film.

Comparative assessment of in vitro/in vivo performances of orodispersible electrospun and casting films containing rizatriptan benzoate

Bioequivalence of Imported and Domestic Risperidone Film-Coated Tablets in Healthy Volunteers

In vivo characterization of Perseris and compositionally equivalent formulations

Population Pharmacokinetic-Pharmacodynamic (poppk/pd) Modeling of Risperidone and Its Active Metabolite in Chinese Schizophrenia Patients.

Establishing Virtual Bioequivalence and Clinically Relevant Specifications for Omeprazole Enteric-Coated Capsules by Incorporating Dissolution Data in PBPK Modeling

Study on Bioequivalence of Risperidone Tablets

Development, In Vitro and In Vivo Evaluation of Racecadotril Orodispersible Films for Pediatric Use

Physiologically-Based Pharmacokinetic Modeling and In Vitro-In Vivo Correlation of TV-46000 (Risperidone LAI): Prediction from Dog to Human

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

Physiologically Based Pharmacokinetic Model Development and Verification for Bioequivalence Testing of Bempedoic Acid Oral Suspension and Reference Tablet Formulation

Effect of type and ratio of solubilising polymer on characteristics of hot-melt extruded orodispersible films

Oral fast dissolving films for co-administration of breviscapine and matrine: Formulation optimization and in vitro characterization

Development of a population pharmacokinetic model for the novel long‐acting injectable antipsychotic risperidone ISM®

Development of an In Vivo Predictive Dissolution Methodology of Topiroxostat Immediate-Release Tablet Using In Silico Simulation

Can 3D Printed Tablets Be Bioequivalent and How to Test It: A PBPK Model Based Virtual Bioequivalence Study for Ropinirole Modified Release Tablets

Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets

Effect of casting solvent, film-forming agent and solubilizer on orodispersible films of a polymorphic poorly soluble drug: an in vitro/ in silico study

A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms

Development and In vitro and In vivo Evaluations of a Microemulsion Formulation for the Oral Delivery of Oxaprozin